Crinetics Pharmaceuticals (CRNX) Enterprise Value (2018 - 2026)

Crinetics Pharmaceuticals' Enterprise Value history runs 10 years deep, the most recent figure standing at -$1.3 billion for Q1 2026.

• In Q1 2026, Enterprise Value fell 1.35% year-over-year to -$1.3 billion; the TTM figure through Mar 2026 stood at -$1.3 billion (down 1.35% YoY), while the FY2025 annual figure was -$1.0 billion, up 24.09% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.3 billion, down from -$1.0 billion in the prior quarter.
• The five-year high for Enterprise Value was -$54.2 million in Q2 2025, with the low at -$1.4 billion in Q4 2024.
• The 5-year median for Enterprise Value is -$554.7 million (2023), against an average of -$637.9 million.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value tumbled 226.22% in 2024, then jumped 93.72% in 2025.
• Crinetics Pharmaceuticals' Enterprise Value stood at -$334.4 million in 2022, then slumped by 67.02% to -$558.6 million in 2023, then sank by 142.42% to -$1.4 billion in 2024, then gained by 24.09% to -$1.0 billion in 2025, then fell by 25.63% to -$1.3 billion in 2026.
• Business Quant data shows CRNX's Enterprise Value at -$1.3 billion in Q1 2026, -$1.0 billion in Q4 2025, and -$111.4 million in Q3 2025.